1. Flow cytometric analysis of single pMHCI-IgG binding and pMHCI delivery to hIGF-1R+ NIH3T3 and MCSP+ UCLA-SO-M14 cells target cells at different concentrations.
Flow cytometric analysis of single pMHCI-IgG binding and pMHCI delivery to hIGF-1R+ NIH3T3 and MCSP+ UCLA-SO-M14 cells target cells at different concentrations. A, binding of anti-IGF-1R normal bivalent control antibody without pMHCI-fusion (column 1), single CMV pMHCI-monovalent anti-IGF-1R IgG (column 2), single CMV pMHCI-bivalent anti-IGF-1R IgG (column 3), single EBV pMHCI-monovalent anti-IGF-1R IgG (column 4), and nonbinding single CMV pMHCI-bivalent DP47 IgG (column 5). Antibody/fusion protein concentration is indicated on the left. B, HLA-A2 complexes detected on the cell surface of MCSP+ HLA-A2− UCLA-SO-M14 cells after binding of single CMV pMHCI-anti-MCSP IgG in concentrations of 25 nmol/L to 0.5 nmol/L. Gray, isotype control and secondary antibody; black, test antibody or fusion protein and secondary antibody.
Martina Schmittnaegel et al. Mol Cancer Ther 2016;15:
©2016 by American Association for Cancer Research